Comparative Benchmarking
In the context of the broader market, NGEN competes directly with industry leaders such as DMAC and IVVD. With a market capitalization of $307.34M, it holds a significant position in the sector. When comparing efficiency, NGEN's gross margin of N/A stands against DMAC's N/A and IVVD's 91.71%. Such benchmarking helps identify whether NervGen Pharma Corp is trading at a premium or discount relative to its financial performance.
